Document is current
Any future updates will be listed below
-
Authors
Higuchi, Tomoaki https://orcid.org/0000-0002-9108-2560
Tanaka, Eiichi https://orcid.org/0000-0003-2850-326X
Inoue, Eisuke https://orcid.org/0000-0002-1652-7769
Sugano, Eri
Ikari, Katsunori https://orcid.org/0000-0001-9066-2005
Harigai, Masayoshi
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (JPMH 23FC1019)
Japan Society for the Promotion of Science (23K15358)
Tokyo Women's Medical University
- License Information
-
More Information
Article History
Received: 22 January 2026
Revised: 14 April 2026
Accepted: 17 April 2026
First Online: 28 April 2026
Declarations
:
: The IORRA cohort study was approved by the Ethics Committee of Tokyo Women’s Medical University (approval no. 2952-R2 and 2922-R16) and performed in accordance with the Declaration of Helsinki.
: Written informed consent was obtained from all participants.
: Tomoaki Higuchi received lecture fees from Asahi Kasei Corp.; Astellas Pharma Inc.; AstraZeneca K.K.; Boehringer Ingelheim Japan, Inc.; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; Eli Lilly Japan K.K.; Gilead Sciences Inc.; Janssen Pharmaceutical K.K.; Kissei Pharmaceutical Co., Ltd.; Pfizer Japan Inc.; Taisho Pharmaceutical Co., Ltd.; UCB Japan Co., Ltd., and collaborative research fund from H.U. Group Research Institute G.K. Eiichi Tanaka received lecture or consulting fees from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kyowa Pharma Chemical Co., Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Eisuke Inoue received lecture or consulting fees from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd. Katsunori Ikari received speaker fees from Asahi Kasei Corp., Astellas Pharma Inc., AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kaken Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma Ltd., and UCB Japan Co. Ltd. Masayoshi Harigai received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Kaken Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekisui Medical, Taisho Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. In addition, Masayoshi Harigai received speaker fees from AbbVie Japan GK, AstraZeneca K.K., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan Inc., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Gilead Sciences Inc., Janssen Pharmaceutical K.K., Kissei Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Japan, Pfizer Japan Inc., CIMIC Holdings Co., Ltd., Mitsubishi Tanabe Pharma Co., Teijin Pharma Ltd., and UCB Japan Co. Ltd. Masayoshi Harigai is a consultant for AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.
